Press release
Cathepsin K Inhibitors Therapeutics Pipeline Analysis 2019
Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1176
The protein has high specificity for kinins and has the capability to catabolize collagen, elastin, and gelatin. Cathepsin K is found to be over-expressed in cancer such as breast cancer and glioblastoma. The mutation in CTSK gene can cause pycnodysostosis. Due to over expression of cathepsin K in osteoclasts, bone deformation occurs which leads to osteoporosis.
Download the sample report @ https://www.pharmaproff.com/request-sample/1176
Company like Medivir AB is in the process of developing MIV-711 as a cathepsin K inhibitor for the treatment of osteoarthritis. Amura Holdings Ltd., and Merck & Co. Inc. are some other companies having pipeline of cathepsin K inhibitors.
Get the detailed analysis @ https://www.pharmaproff.com/report/cathepsin-k-inhibitors-therapeutics
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cathepsin K Inhibitors Therapeutics Pipeline Analysis 2019 here
News-ID: 1686050 • Views: 367
More Releases from Pharma Proff
Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates.
IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to…
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates.
Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete…
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome.
Download the sample report at: https://www.pharmaproff.com/request-sample/1189
Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in…
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances…
More Releases for Cathepsin
Anti-Cathepsin B Industry Landscape and its Growth Prospect By 2020-2030
Anti-Cathepsin B Market: Introduction
Cathepsin B belongs to a family of lysosomal cysteine proteases. It plays an important role in intracellular proteolysis. In humans, Cathepsin B is encoded by the CTSB gene. Anti-Cathepsin B antibody is used to treat cancers, traumatic brain injuries, Ebola infection, and fertility issues.
Report Overview: https://www.transparencymarketresearch.com/anticathepsin-b-market.html
Key Drivers and Restraints of Global Anti-Cathepsin B Market
•Rise in incidence rate of cancer across the globe is a major…
Anti-Cathepsin B Market Seeking Growth from Emerging Markets, Views Sought On Ne …
The Anti-Cathepsin B Market report gives a weighty source to assess the market and other fundamental technicalities identifying with it. The examination unveils the total assessment and veritable parts of the Anti-Cathepsin B Market. The research analysts provide an elaborate description of the value chain and its distributor analysis. This Market study provides comprehensive data which enhances the understanding, scope and application of this report.The trends and expected prospects for…
Anti-Cathepsin B Market to receive overwhelming hike in Revenues by 2029
Global Anti-Cathepsin B Market: Overview
Cathepsin B is an important mediator of inflammation and programmed cell death in individual cells. It has a role in inducing cell dissolution and recycling of cellular organelles. This organic molecule has been implicated in various cancers and other chronic conditions like Alzheimer’s disease and seizures, being primarily involved in the diminution of memory with progress of disease. Anti-Cathepsin B molecules are antibodies against Cathepsin B,…
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)-Pipeline Revi …
A new report on “Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)-Pipeline Review, H2 2017” offers information on the different clinical stages of Cathepsin B. The report, added to the vast repository of Market Research Hub (MRH) offers information and insights on the current scenario in development of Cathepsin B. A comprehensive source of information, the report provides detailed insights on the factors that are likely…
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) Mar …
"The Latest Research Report Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
About Cathepsin L1 Market
According to the recently published report 'Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Pipeline Review, H2 2017'; Cathepsin L1 (Cathepsin L or Major Excreted Protein or…
Cathepsin B Market Report -Pipeline Review, H2 2017
"The Latest Resrach Report Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
About Cathepsin B Market
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)-Cathepsin B (CatB) is an enzymatic protein belonging to the peptidase. It promotes hydrolysis of proteins with broad specificity for…
